Halozyme Therapeutics, Inc. SEC filings HALO
Halozyme Therapeutics, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Dec 12, 2011. Its latest annual report, Form ARS, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 23, 2026 | — |
| DEF 14A | Proxy statement | Mar 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Mar 18, 2025 | — |
| DEF 14A | Proxy statement | Mar 18, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Mar 15, 2024 | — |
| DEF 14A | Proxy statement | Mar 15, 2024 | Dec 31, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 4, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Mar 24, 2023 | — |
| DEF 14A | Proxy statement | Mar 24, 2023 | — |
| DEFA14A | Additional proxy material | Apr 18, 2022 | — |
| DEFA14A | Additional proxy material | Mar 25, 2022 | — |
| DEF 14A | Proxy statement | Mar 25, 2022 | Dec 31, 2021 |
| DEFA14A | Additional proxy material | Mar 26, 2021 | — |
| DEF 14A | Proxy statement | Mar 26, 2021 | Dec 31, 2020 |
| DEFA14A | Additional proxy material | Apr 3, 2020 | — |
| DEFA14A | Additional proxy material | Mar 20, 2020 | — |
| DEF 14A | Proxy statement | Mar 20, 2020 | Dec 31, 2019 |
| DEFA14A | Additional proxy material | Mar 22, 2019 | — |
| DEF 14A | Proxy statement | Mar 22, 2019 | Dec 31, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 1, 2019 | Dec 31, 2018 |
| DEFA14A | Additional proxy material | Apr 6, 2018 | — |
| DEFA14A | Additional proxy material | Apr 3, 2018 | — |
| DEFA14A | Additional proxy material | Mar 22, 2018 | — |
| DEF 14A | Proxy statement | Mar 22, 2018 | Dec 31, 2017 |
| DEFA14A | Additional proxy material | Mar 24, 2017 | — |
| DEF 14A | Proxy statement | Mar 24, 2017 | Dec 31, 2016 |
| DEFA14A | Additional proxy material | Mar 23, 2016 | — |
| DEF 14A | Proxy statement | Mar 23, 2016 | Dec 31, 2015 |
| DEF 14A | Proxy statement | Apr 3, 2015 | Dec 31, 2014 |
| DEF 14A | Proxy statement | Apr 7, 2014 | Dec 31, 2013 |
| DEFA14A | Additional proxy material | Apr 11, 2013 | — |
| DEF 14A | Proxy statement | Apr 11, 2013 | May 16, 2013 |
| PRE 14A | Preliminary proxy statement | Mar 18, 2013 | May 16, 2013 |
| DEF 14A | Proxy statement | Mar 29, 2012 | May 3, 2012 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- HALO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1159036
- Former names
- HALOZYME THERAPEUTICS INC (until Jul 3, 2019); GLOBAL YACHT SERVICES INC (until Mar 12, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.